市場調查報告書

關節內粘稠補充療法市場規模,佔有率及趨勢分析報告:各產品(單次、三次、五次注射)、各地區、各市場區隔預測,2019年 - 2026年

Viscosupplementation Market Size, Share & Trends Analysis Report By Product (Single Injection, Three Injection, Five Injection), By End Use (Hospitals, Orthopedic Clinics/ASCs), And Segment Forecasts, 2020 - 2027

出版商 Grand View Research, Inc. 商品編碼 866723
出版日期 內容資訊 英文 160 Pages
商品交期: 2-3個工作天內
價格
關節內粘稠補充療法市場規模,佔有率及趨勢分析報告:各產品(單次、三次、五次注射)、各地區、各市場區隔預測,2019年 - 2026年 Viscosupplementation Market Size, Share & Trends Analysis Report By Product (Single Injection, Three Injection, Five Injection), By End Use (Hospitals, Orthopedic Clinics/ASCs), And Segment Forecasts, 2020 - 2027
出版日期: 2020年02月18日內容資訊: 英文 160 Pages
簡介

全球關節內粘稠補充療法市場規模預測至2026年將達到71億美元的規模。

本報告提供全球關節內粘稠補充療法市場的相關調查,市場概況和趨勢分析,各地區的市場分析,競爭情形,主要企業的簡介等資訊彙整。

目錄

第1章 調查方法

  • 資訊採購
  • 資料分析

第2章 摘要整理

  • 市場概述
  • 各市場區隔預測
  • 有競爭力的洞察

第3章 關節內粘稠補充療法市場變數,趨勢,及範圍

  • 市場系列預測
  • 市場細分化和範圍
  • 用戶的觀點分析
  • 市場動態
  • 關節內粘稠補充療法:市場分析工具
  • 滲透及成長預測製圖

第4章 關節內粘稠補充療法市場:產品的估計及趨勢分析

  • 關節內粘稠補充療法市場:產品的動靜分析
  • 單次注射
  • 三次注射
  • 五次注射
  • 產品資訊
    • Durolane
    • Gelsyn-3
    • Genvisc
    • Hymovis
    • Supartz Fx
    • Trivisc
    • Visco-3
    • Ostenil
    • Adant

第5章 關節內粘稠補充療法市場:各產品每個地區的概算與趨勢分析

  • 各地區市場儀表板
  • 各地區的關節內粘稠補充療法市場佔有率,2018年及2026年
  • 各地區市場佔有率分析,2018年及2026年
  • 各要因SWOT分析
  • 北美
  • 歐洲
  • 歐洲的產品的價格
  • 亞太地區
  • 南美
  • 中東、非洲地區

第6章 償付預測

  • 骨關節炎的治療的直接醫療費(百分率比率)
  • 產品成本
  • 各產品償付
    • Gel-One
    • Euflexxa
    • Synvisc-One
    • Supartz
    • Hyalgan
    • Monovisc
    • Orthovisc

第7章 競爭情形

  • 臨床實驗平台
  • 臨床試驗
  • 主要市場參與者的最近趨勢及影響分析
  • 業者情勢
  • 關節內粘稠補充療法的競爭情形:市場上的地位分析(產品基礎,各地區影響力)
  • 策略性架構
  • 公司簡介

第8章 推薦

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GVR-1-68038-982-1

The global viscosupplementation market size is expected to reach USD 7.8 billion by 2027, based on a new report published by Grand View Research, Inc. It is anticipated to exhibit a CAGR of 9.2% during the forecast period. Improving regulatory and reimbursement scenarios regarding the use of viscosupplements for the treatment of Osteoarthritis (OA) is expected to aid the growth. For instance, in U.S., unique reimbursement codes are allocated for different products available in the country.

Viscosupplementation procedure is an effective alternative for patients nonresponsive to other treatment options for osteoarthritis. These products have been clinically proven to be effective in providing long-term relief to OA patients with very few side-effects. Factors, such as the growing awareness regarding effective non-surgical procedures for the management of OA and global increase in the target population due to the increasing prevalence of obesity and other lifestyle-induced disorders, are expected to propel the market growth during the forecast period.

Further key findings from the study suggest:

  • Three injections segment dominated the market in 2019 owing to the availability of multiple products and significant market presence
  • Single injection segment is anticipated to witness the fastest growth during the forecast period owing to the increase in demand for a shorter regimen of procedures and faster recovery time
  • The utilization of viscosupplementation is maximum in Ambulatory Surgical Centers (ASCs), and orthopedic clinics. The higher usage of the viscosupplements is observed to be in outpatient settings owing to better reimbursement options
  • General physicians, rheumatologists, and orthopedists are the main influencer in the viscosupplementation market. The role of an influencer in the procurement of the product in the hospitals and clinics varies from region to region
  • Asia Pacific held the largest market share in 2019 and is expected to maintain its position during the forecast period due to the presence of key players and high incidence of osteoarthritis in the countries such as Japan and China.
  • Europe is expected to witness a lucrative CAGR in the forthcoming years, due to growing awareness about applications of non-surgical techniques and increasing disposable income
  • Key players are investing in improving their product portfolio to develop advanced products to maintain their market position. For instance, in March 2019, Seikagaku Corporation introduced a new intra-articular viscosupplement named HyLink (single injection) in Italy for the treatment of knee OA
  • Companies are also undertaking strategic initiatives, such as marketing licensing and distribution partnerships to increase geographic presence
  • Some key industry contributors are Anika Therapeutics, Inc.; Sanofi; Ferring B.V.; Seikagaku Corporation; Bioventus; Zimmer Holdings Inc; LG Life Sciences Ltd; and Lifecore Biomedical, LLC

Table of Contents

Chapter 1 Research Objective

  • 1.1 Objectives
    • 1.1.1 Objective 1
    • 1.1.2 Objective 2

Chapter 2 Executive Summary

  • 2.1 Market Outlook
  • 2.2 Segment Outlook
    • 2.2.1 Product
    • 2.2.2 End-Use
    • 2.2.3 Region
  • 2.3 Competitive Insights

Chapter 3 Market Variables, Trends & Scope

  • 3.1 Market Lineage Outlook
    • 3.1.1 Parent Market Outlook
    • 3.1.2 Related/Ancillary Market Outlook
  • 3.2 Market Segmentation
  • 3.3 User Perspective Analysis
    • 3.3.1 Consumer Behavior Analysis
    • 3.3.2 Market Influencer Analysis
  • 3.4 Penetration & Growth Prospect Mapping
    • 3.4.1 Analysis
  • 3.5 Market Dynamics
    • 3.5.1 Market Driver Analysis
      • 3.5.1.1 Increasing prevalence of osteoarthritis among geriatric population
      • 3.5.1.2 New product launch
    • 3.5.2 Market Restraint Analysis
      • 3.5.2.1 High cost and side effects associated with hyaluronic acid cycles
  • 3.6 Business Environment Analysis Tools
    • 3.6.1 Porter's Five Forces Analysis
    • 3.6.2 Viscosupplementation Market - Pestle Analysis
  • 3.7 Clinical Trials
  • 3.8 Major Deals & Strategic Alliances Analysis
    • 3.8.1 Licensing & Partnerships, Technology Collaborations
    • 3.8.2 Mergers & Acquisitions

Chapter 4 Viscosupplementation Market: Product Analysis

  • 4.1 Viscosupplementation Product Market Share analysis, 2019 & 2027
  • 4.2 Segment Dashboard
  • 4.3 Market Size & Forecasts and Trend Analysis, 2016 to 2027 for the Product
    • 4.3.1 Single Injection
      • 4.3.1.1 Single injection market, 2016 - 2027 (USD Million)
    • 4.3.2 Three Injection
      • 4.3.2.1 Three injection market, 2016 - 2027 (USD Million)
    • 4.3.3 Five Injection
      • 4.3.3.1 Five injection market, 2016 - 2027 (USD Million)
    • 4.3.4 Product Information
      • 4.3.4.1 Durolane
      • 4.3.4.2 GelSyn-3
      • 4.3.4.3 GenVisc 850
      • 4.3.4.4 Hymovis
      • 4.3.4.5 Supartz FX
      • 4.3.4.6 TriVisc
      • 4.3.4.7 Visco-3
      • 4.3.4.8 Ostenil
      • 4.3.4.9 Adant

Chapter 5 Viscosupplementation Market: End-Use Analysis

  • 5.1 Viscosupplementation End-Use Market Share analysis, 2019 & 2027
  • 5.2 Segment Dashboard
  • 5.3 Market Size & Forecasts and Trend Analysis, 2016 to 2027 for the End-Use
    • 5.3.1 Hospitals
      • 5.3.1.1 Hospitals market, 2016 - 2027 (USD Million)
    • 5.3.2 Orthopedic Clinics/Ambulatory Surgery Centers (Ascs)
      • 5.3.2.1 Orthopedic clinic/ambulatory surgical centers market, 2016 - 2027 (USD Million)

Chapter 6 Regional Outlook

  • 6.1 Regional Market Share Analysis, 2019 & 2027
  • 6.2 Regional Market Snapshot (Countries)
  • 6.3 SWOT Analysis, by Factor
    • 6.3.1 North America
    • 6.3.2 Europe
    • 6.3.3 Asia Pacific
    • 6.3.4 Latin America
    • 6.3.5 Middle East & Africa
  • 6.4 Market Size, & Forecasts and Trend Analysis, 2019 to 2027
    • 6.4.1 North America
      • 6.4.1.1 North America viscosupplementation market, 2016 - 2027 (USD Million)
      • 6.4.1.2 U.S.
      • 6.4.1.2.1 Regulatory and reimbursement scenario
      • 6.4.1.2.2 U.S. viscosupplementation market, 2016 - 2027 (USD Million)
      • 6.4.1.3 Canada
      • 6.4.1.3.1 Regulatory and reimbursement scenario
      • 6.4.1.3.2 Canada viscosupplementation market, 2016 - 2027 (USD Million)
    • 6.4.2 Europe
      • 6.4.2.1 Europe viscosupplementation market, 2016 - 2027 (USD Million)
      • 6.4.2.2 U.K.
      • 6.4.2.2.1 Regulatory and reimbursement scenario
      • 6.4.2.2.2 U.K. viscosupplementation market, 2016 - 2027 (USD Million)
      • 6.4.2.3 Germany
      • 6.4.2.3.1 Regulatory and reimbursement scenario
      • 6.4.2.3.2 Germany viscosupplementation market, 2016 - 2027 (USD Million)
      • 6.4.2.4 France
      • 6.4.2.4.1 Regulatory and reimbursement scenario
      • 6.4.2.4.2 France viscosupplementation market, 2016 - 2027 (USD Million)
      • 6.4.2.5 Italy
      • 6.4.2.5.1 Regulatory and reimbursement scenario
      • 6.4.2.5.2 Italy viscosupplementation market, 2016 - 2027 (USD Million)
      • 6.4.2.6 Spain
      • 6.4.2.6.1 Regulatory and reimbursement scenario
      • 6.4.2.6.2 Spain viscosupplementation market, 2016 - 2027 (USD Million)
    • 6.4.3 Asia Pacific
      • 6.4.3.1 Asia Pacific viscosupplementation market, 2016 - 2027 (USD Million)
      • 6.4.3.2 China
      • 6.4.3.2.1 Regulatory and reimbursement scenario
      • 6.4.3.2.1 China viscosupplementation market, 2016 - 2027 (USD Million)
      • 6.4.3.3 Japan
      • 6.4.3.3.1 Regulatory and reimbursement scenario
      • 6.4.3.3.2 Japan viscosupplementation market, 2016 - 2027 (USD Million)
      • 6.4.3.4 India
      • 6.4.3.4.1 Regulatory and reimbursement scenario
      • 6.4.3.4.2 India viscosupplementation market, 2016 - 2027 (USD Million)
      • 6.4.3.5 South Korea
      • 6.4.3.5.1 Regulatory and reimbursement scenario
      • 6.4.3.5.2 South Korea viscosupplementation market, 2016 - 2027 (USD Million)
      • 6.4.3.6 Australia
      • 6.4.3.6.1 Regulatory and reimbursement scenario
      • 6.4.3.6.2 Australia viscosupplementation market, 2016 - 2027 (USD Million)
    • 6.4.4 Latin America
      • 6.4.4.1 Latin America viscosupplementation market, 2016 - 2027 (USD Million)
      • 6.4.4.2 Brazil
      • 6.4.4.2.1 Regulatory and reimbursement scenario
      • 6.4.4.2.2 Brazil viscosupplementation market, 2016 - 2027 (USD Million)
      • 6.4.4.3 Mexico
      • 6.4.4.3.1 Regulatory and reimbursement scenario
      • 6.4.4.3.2 Mexico viscosupplementation market, 2016 - 2027 (USD Million)
      • 6.4.4.4 Argentina
      • 6.4.4.4.1 Regulatory and reimbursement scenario
      • 6.4.4.4.2 Argentina viscosupplementation market, 2016 - 2027 (USD Million)
      • 6.4.4.5 Columbia
      • 6.4.4.5.1 Regulatory and reimbursement scenario
      • 6.4.4.5.2 Columbia viscosupplementation market, 2016 - 2027 (USD Million)
    • 6.4.5 Middle East & Africa
      • 6.4.5.1 MEA viscosupplementation market, 2016 - 2027 (USD Million)
      • 6.4.5.2 South Africa
      • 6.4.5.2.1 Regulatory and reimbursement scenario
      • 6.4.5.2.2 South africa viscosupplementation market, 2016 - 2027 (USD Million)
      • 6.4.5.3 Saudi Arabia
      • 6.4.5.3.1 Regulatory and reimbursement scenario
      • 6.4.5.3.2 Saudi Arabia viscosupplementation market, 2016 - 2027 (USD Million)
      • 6.4.5.4 UAE
      • 6.4.5.4.1 Regulatory and reimbursement scenario
      • 6.4.5.4.2 UAE viscosupplementation market, 2016 - 2027 (USD Million)

Chapter 7 Reimbursement Outlook

  • 7.1 Direct Medical Costs of Treatment of Osteoarthritis (Percentage Distribution)
  • 7.2 Cost of Products
  • 7.3 Reimbursement by Product
    • 7.3.1 Gel-One
    • 7.3.2 Euflexxa
    • 7.3.3 Synvisc-One
    • 7.3.4 Supartz
    • 7.3.5 Hyalgan
    • 7.3.6 Monovisc
    • 7.3.7 Orthovisc

Chapter 8 Competitive Analysis

  • 8.1 Strategic Framework/ Competition Categorization (Key innovators, Market leaders, emerging players
  • 8.2 Vendor Landscape
    • 8.2.1 Company Market Position Analysis (Market Presence, Geographic Presence, Product Portfolio, Startegic Initiatves)
  • 8.3 Company Profiles
    • 8.3.1 SANOFI
      • 8.3.1.1 Company overview
      • 8.3.1.2 Financial performance
      • 8.3.1.3 Product benchmarking
      • 8.3.1.4 Strategic initiatives
      • 8.3.1.5 SWOT analysis
    • 8.3.2 ANIKA THERAPEUTICS, INC.
      • 8.3.2.1 Company overview
      • 8.3.2.2 Financial performance
      • 8.3.2.3 Product benchmarking
      • 8.3.2.4 Strategic initiatives
      • 8.3.2.5 SWOT analysis
    • 8.3.3 SEIKAGAKU CORPORATION
      • 8.3.3.1 Company overview
      • 8.3.3.2 Financial performance
      • 8.3.3.3 Product benchmarking
      • 8.3.3.4 Strategic initiatives
      • 8.3.3.5 SWOT analysis
    • 8.3.4 ZIMMER BIOMET
      • 8.3.4.1 Company overview
      • 8.3.4.2 Financial performance
      • 8.3.4.3 Product benchmarking
      • 8.3.4.4 Strategic initiatives
      • 8.3.4.5 SWOT analysis
    • 8.3.5 SMITH & NEPHEW PLC
      • 8.3.5.1 Company overview
      • 8.3.5.2 Financial performance
      • 8.3.5.3 Product benchmarking
      • 8.3.5.4 Strategic initiatives
      • 8.3.5.5 SWOT analysis
    • 8.3.6 FERRING B.V.
      • 8.3.6.1 Company overview
      • 8.3.6.2 Financial performance
      • 8.3.6.3 Product benchmarking
      • 8.3.6.4 Strategic initiative
    • 8.3.7 LIFECORE BIOMEDICAL, LLC (LANDEC)
      • 8.3.7.1 Company overview
      • 8.3.7.2 Financial performance
      • 8.3.7.3 Product benchmarking
      • 8.3.7.4 Strategic initiatives
      • 8.3.5.5 SWOT analysis
    • 8.3.8 LG LIFE SCIENCES LTD ( LG CHEM)
      • 8.3.8.1 Company overview
      • 8.3.8.2 Financial performance
      • 8.3.8.3 Product benchmarking
      • 8.3.8.4 Strategic initiatives
      • 8.3.8.5 SWOT analysis
    • 8.3.9 SALIX PHARMACEUTICALS
      • 8.3.9.1 Company overview
      • 8.3.9.2 Financial performance
      • 8.3.9.3 Product benchmarking
      • 8.3.9.4 Strategic initiatives
      • 8.3.9.5 SWOT analysis
    • 8.3.10 FIDIA FARMACEUTIC S.P.A
      • 8.3.10.1 Company overview
      • 8.3.10.2 Financial performance
      • 8.3.10.3 Product benchmarking
      • 8.3.10.4 Strategic initiatives
    • 8.3.11 F.HOFFMANN-LA ROCHE LTD.
      • 8.3.11.1 Company overview
      • 8.3.11.2 Financial performance
      • 8.3.11.3 Product benchmarking
      • 8.3.11.4 Strategic initiatives
      • 8.3.11.5 SWOT analysis

Chapter 9 Recommendations

  • 9.1 Recommendations

Chapter 10 Research Methodology & Scope

  • 10.1 Market Segmentation & Scope
  • 10.2 Research Methodology
  • 10.3 Information Procurement
    • 10.3.1 Purchased Database
    • 10.3.2 Gvr's Internal Database
    • 10.3.3 Secondary Sources
    • 10.3.4 Primary Research
    • 10.3.5 Details Of Primary ResearcH
  • 10.4 Information or Data Analysis
    • 10.4.1 Data Analysis Models
  • 10.5 Market Formulation & Validation
  • 10.6 Model Details
    • 10.6.1 Volume Price Analysis
    • 10.6.2 Commodity Flow Analysis
  • 10.7 List of Secondary Sources
  • 10.8 List of Abbreviations

Chapter 11 Report FAQs

  • 11.1 How do I trust your report quality/data accuracy?
  • 11.2 My research requirement is very specific; can I customize this report?
  • 11.3 I have a pre-defined budget. Can I buy chapters/sections of this report?
  • 11.4 How do you arrive at these market numbers?
  • 11.5 Who are your clients?
  • 11.6 How will I receive this report?

Chapter 12 Appendix

Chapter 13 Compass - Cloud Based Report Delivery Platform

Chapter 14 Related Reports

List of Tables

  • TABLE 1 North America viscosupplementation market, by country, 2016 - 2027 (USD Million)
  • TABLE 2 North America viscosupplementation market, by product, 2016 - 2027 (USD Million)
  • TABLE 3 North America viscosupplementation market, by end-Use, 2016 - 2027 (USD Million)
  • TABLE 4 U.S. viscosupplementation market, by product, 2016 - 2027 (USD Million)
  • TABLE 5 U.S. viscosupplementation market, by end-Use, 2016 - 2027 (USD Million)
  • TABLE 6 Canada viscosupplementation market, by product, 2016 - 2027 (USD Million)
  • TABLE 7 Canada viscosupplementation market, by end-Use, 2016 - 2027 (USD Million)
  • TABLE 8 Europe viscosupplementation market, by country, 2016 - 2027 (USD Million)
  • TABLE 9 Europe viscosupplementation market, by product, 2016 - 2027 (USD Million)
  • TABLE 10 Europe viscosupplementation market, by end-Use, 2016 - 2027 (USD Million)
  • TABLE 11 U.K. viscosupplementation market, by product, 2016 - 2027 (USD Million)
  • TABLE 12 U.K. viscosupplementation market, by end-Use, 2016 - 2027 (USD Million)
  • TABLE 13 France viscosupplementation market, by product, 2016 - 2027 (USD Million)
  • TABLE 14 France viscosupplementation market, by end-Use, 2016 - 2027 (USD Million)
  • TABLE 15 Germany viscosupplementation market, by product, 2016 - 2027 (USD Million)
  • TABLE 16 Germany viscosupplementation market, by end-Use, 2016 - 2027 (USD Million)
  • TABLE 17 Italy viscosupplementation market, by product, 2016 - 2027 (USD Million)
  • TABLE 18 Italy viscosupplementation market, by end-Use, 2016 - 2027 (USD Million)
  • TABLE 19 Spain viscosupplementation market, by product, 2016 - 2027 (USD Million)
  • TABLE 20 Spain viscosupplementation market, by end-Use, 2016 - 2027 (USD Million)
  • TABLE 21 Asia Pacific viscosupplementation market, by country, 2016 - 2027 (USD Million)
  • TABLE 22 Asia Pacific viscosupplementation market, by product, 2016 - 2027 (USD Million)
  • TABLE 23 Asia Pacific viscosupplementation market, by end-Use, 2016 - 2027 (USD Million)
  • TABLE 24 China viscosupplementation market, by product, 2016 - 2027 (USD Million)
  • TABLE 25 China viscosupplementation market, by end-Use, 2016 - 2027 (USD Million)
  • TABLE 26 Japan viscosupplementation market, by product, 2016 - 2027 (USD Million)
  • TABLE 27 Japan viscosupplementation market, by end-Use, 2016 - 2027 (USD Million)
  • TABLE 28 India viscosupplementation market, by product, 2016 - 2027 (USD Million)
  • TABLE 29 India viscosupplementation market, by end-Use, 2016 - 2027 (USD Million)
  • TABLE 30 South Korea viscosupplementation market, by product, 2016 - 2027 (USD Million)
  • TABLE 31 South Korea viscosupplementation market, by end-Use, 2016 - 2027 (USD Million)
  • TABLE 32 Australia viscosupplementation market, by product, 2016 - 2027 (USD Million)
  • TABLE 33 Australia viscosupplementation market, by end-Use, 2016 - 2027 (USD Million)
  • TABLE 34 Latin America viscosupplementation market, by country, 2016 - 2027 (USD Million)
  • TABLE 35 Latin America viscosupplementation market, by product, 2016 - 2027 (USD Million)
  • TABLE 36 Latin America viscosupplementation market, by end-Use, 2016 - 2027 (USD Million)
  • TABLE 37 Brazil viscosupplementation market, by product, 2016 - 2027 (USD Million)
  • TABLE 38 Brazil viscosupplementation market, by end-Use, 2016 - 2027 (USD Million)
  • TABLE 39 Mexico viscosupplementation market, by product, 2016 - 2027 (USD Million)
  • TABLE 40 Mexico viscosupplementation market, by end-Use, 2016 - 2027 (USD Million)
  • TABLE 41 Argentina viscosupplementation market, by product, 2016 - 2027 (USD Million)
  • TABLE 42 Argentina viscosupplementation market, by end-Use, 2016 - 2027 (USD Million)
  • TABLE 43 Colombia viscosupplementation market, by product, 2016 - 2027 (USD Million)
  • TABLE 44 Columbia viscosupplementation market, by end-Use, 2016 - 2027 (USD Million)
  • TABLE 45 MEA viscosupplementation market, by country, 2016 - 2027 (USD Million)
  • TABLE 46 MEA viscosupplementation market, by product, 2016 - 2027 (USD Million)
  • TABLE 47 MEA viscosupplementation market, by end-Use, 2016 - 2027 (USD Million)
  • TABLE 48 South Africa viscosupplementation market, by product, 2016 - 2027 (USD Million)
  • TABLE 49 South Africa viscosupplementation market, by end-Use, 2016 - 2027 (USD Million)
  • TABLE 50 Saudi Arabia viscosupplementation market, by product, 2016 - 2027 (USD Million)
  • TABLE 51 Saudi Arabia viscosupplementation market, by end-Use, 2016 - 2027 (USD Million)
  • TABLE 52 UAE viscosupplementation market, by product, 2016 - 2027 (USD Million)
  • TABLE 53 UAE viscosupplementation market, by end-Use, 2016 - 2027 (USD Million)
  • TABLE 54 Cost of viscosupplements-a driving factor (U.S.)
  • TABLE 55 HCPCS codes
  • TABLE 56 Labelling instructions by the FDA
  • TABLE 57 Distribution and marketing rights of Synvisc
  • TABLE 58 List of secondary sources
  • TABLE 59 List of abbreviation

List of Figures

  • FIG. 1 Market research process
  • FIG. 2 Information procurement
  • FIG. 3 Primary research pattern
  • FIG. 4 Market research approaches
  • FIG. 5 Value chain-based sizing &forecasting
  • FIG. 6 QFD modelling for market share assessment
  • FIG. 7 Market summary, 2019 (USD Million)
  • FIG. 8 Market segmentation & scope
  • FIG. 9 Market trends & outlook
  • FIG. 10 Market driver relevance analysis (Current & future impact)
  • FIG. 11 Ratio of adult population to total population (billion)
  • FIG. 12 Market restraint relevance analysis (Current &future impact)
  • FIG. 13 Porter's Five Forces Analysis
  • FIG. 14 Viscosupplementation market - PESTLE Analysis
  • FIG. 15 Penetration & growth prospect mapping
  • FIG. 16 Viscosupplementation market: Product outlook key takeaways (USD Million)
  • FIG. 17 Viscosupplementation market: Product movement analysis (USD Million)
  • FIG. 18 Single-injection market, 2016 - 2027 (USD Million)
  • FIG. 19 Three-injection market, 2016 - 2027 (USD Million)
  • FIG. 20 Five-injection market, 2016 - 2027 (USD Million)
  • FIG. 21 Hospitals market, 2016 - 2027 (USD Million)
  • FIG. 22 Viscosupplementation market: End-Use outlook key takeaways (USD Million)
  • FIG. 23 Viscosupplementation market: End-Use movement analysis (USD Million)
  • FIG. 24 Orthopedic clinics/ambulatory surgical centers market, 2016 - 2027 (USD Million)
  • FIG. 25 Regional market place: Key takeaways
  • FIG. 26 Regional outlook, 2019 & 2027 (USD Million)
  • FIG. 27 North America viscosupplementation market, 2016 - 2027 (USD Million)
  • FIG. 28 U.S. viscosupplementation market, 2016 - 2027 (USD Million)
  • FIG. 29 Canada viscosupplementation market, 2016 - 2027 (USD Million)
  • FIG. 30 Europe viscosupplementation market, 2016 - 2027 (USD Million)
  • FIG. 31 U.K. viscosupplementation market, 2016 - 2027 (USD Million)
  • FIG. 32 France viscosupplementation market, 2016 - 2027 (USD Million)
  • FIG. 33 Germany viscosupplementation market, 2016 - 2027 (USD Million)
  • FIG. 34 Italy viscosupplementation market, 2016 - 2027 (USD Million)
  • FIG. 35 Spain viscosupplementation market, 2016 - 2027 (USD Million)
  • FIG. 36 Asia Pacific viscosupplementation market, 2016 - 2027 (USD Million)
  • FIG. 37 China viscosupplementation market, 2016 - 2027 (USD Million)
  • FIG. 38 Japan viscosupplementation market, 2016 - 2027 (USD Million)
  • FIG. 39 India viscosupplementation market, 2016 - 2027 (USD Million)
  • FIG. 40 South Korea viscosupplementation market, 2016 - 2027 (USD Million)
  • FIG. 41 Australia viscosupplementation market, 2016 - 2027 (USD Million)
  • FIG. 42 Latin America viscosupplementation market, 2016 - 2027 (USD Million)
  • FIG. 43 Brazil viscosupplementation market, 2016 - 2027 (USD Million)
  • FIG. 44 Mexico viscosupplementation market, 2016 - 2027 (USD Million)
  • FIG. 45 Argentina viscosupplementation market, 2016 - 2027 (USD Million)
  • FIG. 46 Colombia viscosupplementation market, 2016 - 2027 (USD Million)
  • FIG. 47 MEA viscosupplementation market, 2016 - 2027 (USD Million)
  • FIG. 48 South Africa viscosupplementation market, 2016 - 2027 (USD Million)
  • FIG. 49 Saudi Arabia viscosupplementation market, 2016 - 2027 (USD Million)
  • FIG. 50 UAE viscosupplementation market, 2016 - 2027 (USD Million)
  • FIG. 51 Recent developments & impact analysis, by key market participants
  • FIG. 52 Viscosupplement market: Company market position analysis